Q4 2024 Management View CEO Jennifer Ernst highlighted significant advancements, including the acquisition of exclusive worldwide rights to the Phase III immunomodulatory drug candidate Entolimod, ...

Gozellix®, after radiolabeling with 68 Ga, is indicated for PET scanning of PSMA positive lesions in men with prostate cancer who have suspected metastasis and are candidates for initial definitive ...

The future of American drug innovation is threatened by U.S. regulations that permit knockoff versions of new drugs to be ...

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Regulatory and reimbursement pathways should consider indirect benefits in addition to direct health benefits when evaluating ...

Colonel Jeffrey D. Glover and Dr. Benjamin F. Chavis Jr. The new FDA-approved weight loss medicines have changed the game for people with obesity, offering millions of Americans a chance to transform ...